Hospital

A UK research team has pioneered a blood test using infrared technology to detect lung cancer cells, promising earlier diagnoses and personalized treatments.

Clinicians learn to optimize type 2 diabetes treatment using automated insulin delivery data, enhancing patient safety and education for effective management.

Experts discuss innovations in medication-use processes at the ASHP Midyear Meeting, highlighting trends in acute and ambulatory care for pharmacy leaders.

This review examines the mechanisms of therapy, summarizes the existing literature, and highlights the evolving treatment options for unresectable hepatocellular carcinoma.

A pharmacist-led deep vein thrombosis (DVT) clinic revolutionizes outpatient care, reducing emergency visits and costs while enhancing medication adherence through collaborative practices.

Biosimilars are set to revolutionize oncology by enhancing access and affordability while maintaining safety and efficacy.

ctDNA analysis revolutionizes cancer treatment by predicting responses, detecting resistance, and monitoring minimal residual disease in patients.

The FDA approves depemokimab-ulaa as a long-acting treatment for severe asthma, enhancing patient care with fewer injections and improved outcomes.

Measles cases surge in the US, prompting quarantine measures in South Carolina schools and raising urgent vaccination concerns amid declining rates.

Host Craig Beavers sits down with Marc Baines, cofounder and executive director of the HeartLife Foundation, to explore heart failure care through the lens of lived experience.

The approval is supported by findings from the phase 3 DESTINY-Breast09 trial.

Pharmacists play a vital role in modern clinical trials, enhancing patient safety and trial efficiency through drug management and protocol development.

Lerodalcibep, a new PCSK9 inhibitor, offers a convenient monthly injection to effectively lower LDL cholesterol in patients with hypercholesterolemia.

Research reveals that isatuximab on-body injector shows consistent safety and efficacy across various body weight groups in multiple myeloma treatment.

SABCS 2025 showcases breakthroughs in breast cancer therapy, emphasizing novel therapies and precision medicine to enhance patient outcomes.

Pivotal FDA approvals in breast cancer treatment focused on precision medicine and innovative therapies in 2025.

Exploratory findings from the MONALEESA-3 trial presented at SABCS 2025 show ribociclib plus fulvestrant significantly enhances survival in ILC.

Discover how antibody drug conjugates (ADCs) are transforming treatment for HER2-positive breast cancer with brain metastases at SABCS 2025.

After 2 initial doses, inebilizumab is administered with only 2 doses a year.

As the new chair of the Advisory Committee on Immunization Practices (ACIP) signals interest in revisiting childhood and adolescent vaccine schedules, immunologist Morgan McSweeney, PhD, stresses that any changes must be anchored in decades of rigorous safety and efficacy data.

Experts explore the evolving role of HER2- and TROP2-targeted therapies in breast cancer treatment at SABCS 2025, highlighting ADC advancements.

FDA approves gepotidacin as a new oral treatment for uncomplicated gonorrhea, expanding options against resistant sexually transmitted infections.

Latest findings presented at SABCS 2025 support trastuzumab deruxtecan's effectiveness and safety in treating HER2-positive breast cancer.

Diana Isaacs, PharmD, highlights evolving criteria for insulin pump therapy in type 2 diabetes.

Ginger Thorpe discusses how in-house specialty pharmacy models enhance patient care, streamline communication, and boost health system revenue amid rising demand.

Tucatinib enhances first-line maintenance therapy for HER2-positive metastatic breast cancer, improving progression-free survival and safety outcomes, as shown in the HER2CLIMB-05 trial.

Cell-cycle–focused CDK inhibitors offer new options for HR+/HER2– metastatic breast cancer after CDK4/6 resistance.